Ranibizumab (Lucentis) for the treatment of visual impairment due to diabetic macular oedema

Head-to-head trials have shown that, with respect to the intended and unintended effects, ranibizumab is superior to laser for the treatment of patients with visual impairment due to DME.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.